請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17971
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊家榮(Chia-Ron Yang) | |
dc.contributor.author | Monica Huang | en |
dc.contributor.author | 黃彥嘉 | zh_TW |
dc.date.accessioned | 2021-06-08T00:47:24Z | - |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-24 | |
dc.identifier.citation | 1. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20: 3898-3941. 2. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta. 2010; 1799: 717-725. 3. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13: 673-691. 4. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124: 30-39. 5. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006; 66: 9245-9251. 6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136: 359-386. 7. Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015; 21: 5158-5166. 8. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907. 9. Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012; 4: 71-75. 10. Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol. 2012; 4: 68-70. 11. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-487. 12. Winawer SJ. The history of colorectal cancer screening: a personal perspective. Dig Dis Sci. 2015; 60: 596-608. 13. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer. 2003; 3: 615-622. 14. Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002; 38: 867-871. 15. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. Int J Mol Sci. 2012; 13: 12153-12168. 16. Clevers RF, Ron S, Hans. APC, Signal transduction and genetic instability in colorectal cancer. Nature Reviews Cancer. 2001; 1: 55-67. 17. Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: Involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta. 2015; 1856: 28-38. 18. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50: 113-130. 19. Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-637. 20. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci. 2014; 60: 623-633. 21. Wolpin BM, Mayer RJ. Systemic Treatment of Colorectal Cancer. Gastroenterology. 2008; 134: 1296-1310. 22. Fakih MG. Metastatic Colorectal Cancer: Current State and Future Directions. J Clin Oncol. 2015; 33: 1809-1824. 23. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis. 2014; 29: 1031-1042. 24. Vosooghi M, Amini M. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov. 2014; 9: 255-267. 25. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014; 13: 513-532. 26. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008; 3: 28-37. 27. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150: 12-27. 28. Virani S, Colacino JA, Kim JH, Rozek LS. Cancer epigenetics: a brief review. Ilar J. 2013; 53: 359-369. 29. Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 2015; 16: 258-264. 30. Johnstone JEB, Melissa JP, Ricky W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery. 2006; 5: 769-784. 31. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3: 166-179. 32. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007; 18: 769-774. 33. Sadoul K, Boyault C, Pabion M, Khochbin S. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie. 2007; 90: 306-312. 34. Kramer OH, Mahboobi S, Sellmer A. Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol Sci. 2014; 35: 501-509. 35. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10: 935-954. 36. Noteborn MH. Apoptin-induced apoptosis: a review. Apoptosis. 2003; 4: 317-319. 37. Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev. 2012; 38: 868-876. 38. Creagh EM. Caspase crosstalk: integration of apoptotic and innate immune signalling pathways. Trends Immunol. 2014; 35: 631-640. 39. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2003; 29: 15-18. 40. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-410. 41. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17: 1359-1370. 42. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47. 43. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ. 2008; 15: 621-627. 44. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell. 2010; 17: 755-773. 45. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 1999; 18: 1905-1914. 46. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, Fujii-Kuriyama Y. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003; 22: 1134-1146. 47. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006; 70: 1469-1480. 48. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-732. 49. Al Okail MS. Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1α in U251 human glioblastoma cell line. Journal of Saudi Chemical Society. 2010; 14: 197-201. 50. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009; 280: 145-153. 51. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ. HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem. 2011; 286: 38095-38102. 52. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006; 26: 2019-2028. 53. Mehndiratta S, Hsieh YL, Liu YM, Wang AW, Lee HY, Liang LY, Kumar S, Teng CM, Yang CR, Liou JP. Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity. Eur J Med Chem. 2014; 85: 468-479. 54. Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011; 2011: 197946. 55. Emiliani S, Fischle W, Van Lint C, Al-Abed Y, Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sci U S A. 1998; 95: 2795-2800. 56. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W, Verdin E. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem. 1999; 274: 11713-11720. 57. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013; 341: 80-96. 58. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2013; 125: 5591-5596. 59. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674. 60. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545. 61. Wang Z, Chen JQ, Liu JL. COX-2 Inhibitors and Gastric Cancer. Gastroenterol Res Pract. 2014; 2014: 132320. 62. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 2014; 5: 677-692. 63. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol. 2009; 27: 91-97. 64. Tong X, Yin L, Joshi S, Rosenberg DW, Giardina C. Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem. 2005; 280: 15503-15509. 65. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. Jama. 2009; 302: 649-658. 66. Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J, Chen XW, Chen P, Xu HM, Wang ZN. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015; 26: 589-600. 67. Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One. 2012; 7: e43645. 68. Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH, Yang CR. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis. 2014; 5: e1166. 69. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis. 2009; 25: 135-140. 70. Yu HG, Zhong X, Yang YN, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased expression of nuclear factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int J Colorectal Dis. 2003; 19: 18-22. 71. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004; 10: 8465-8471. 72. Sporn AA, Michael B. The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer. 2007; 7: 139-147. 73. Kim NK, Park JK, Shin E, Kim YW. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer. Anticancer Res. 2014; 34: 6451-6457. 74. Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002; 21: 2672-2681. 75. Kato T, Shimono Y, Hasegawa M, Jijiwa M, Enomoto A, Asai N, Murakumo Y, Takahashi M. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 2009; 69: 3597-3604. 76. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5: 455-463. 77. Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2013; 280: 775-793. 78. Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci. 2014; 10: 757-770. 79. Ma P, Pan H, Montgomery RL, Olson EN, Schultz RM. Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. Proc Natl Acad Sci U S A. 2012; 109: 481-489. 80. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 2001; 277: 2073-2080. 81. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102: 3697-3702. 82. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2003; 101: 540-545. 83. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci. 2010; 17: 76. 84. Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 2007; 67: 6987-6994. 85. Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals. 2010; 3: 2441-2469. 86. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271-275. 87. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66: 8814-8821. 88. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep. 2007; 17: 647-651. 89. Kang FW, Que L, Wu M, Wang ZL, Sun J. Effects of trichostatin A on HIF-1alpha and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol Rep. 2012; 28: 193-199. 90. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002; 111: 709-720. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17971 | - |
dc.description.abstract | 實驗目的:Histone deacetylases (組蛋白去乙醯酶,HDACs)藉由減少組蛋白之乙醯化來調控基因表達,當HDACs作用使組蛋白去乙醯化時,抑癌基因會受到抑制,使得癌細胞不受控制而大量生長,因此透過抑制HDAC的作用可能可以抑制癌細胞增生。迄今雖然有四個HDAC抑制劑已被美國FDA允許上市,但尚未有用於治療固態瘤之HDAC抑制劑,此論文之研究目的為探討一新型HDAC抑制劑MPT0G157在大腸直腸癌中促使細胞凋亡及抑制癌細胞血管新生之效果與機轉。
實驗方法:本研究利用SRB assay評估MPT0G157抑制細胞增生之情形,並利用流式細胞儀觀察細胞週期變化;此外,利用HDAC assay kit測定MPT0G157對HDAC isoform的抑制效果及在大腸直腸癌細胞株HCT116中抑制HDAC活性之能力。蛋白質表現及mRNA變化以西方點墨法及即時定量聚合酶連鎖反應觀察。在血管新生方面,我們將細胞培養在低氧控制箱及使用氯化亞鈷誘導缺氧狀態,觀察MPT0G157 對缺氧誘導因子-1alpha(hypoxia-inducible factor-1alpha,HIF-1alpha)蛋白質之調控,並以免疫沉澱法觀察MPT0G157影響熱休克蛋白90 (heat shock protein 90,HSP90)乙醯化與HIF-1alpha之交互作用;藉由在細胞中過量表現HDAC1及HDAC6確認MPT0G157是否透過抑制HDAC活性影響細胞增生、細胞凋亡與抑制HIF-1alpha蛋白表現。利用異體移植(xenograft)腫瘤與matrigel plug assay動物實驗模型確認MPT0G157抑制腫瘤生成、血管新生及抗發炎的能力。 實驗結果:在四種不同癌症細胞株(乳癌、肺癌、大腸直腸癌、胰臟癌)中,MPT0G157在大腸直腸癌細胞株HCT116有最佳抑制細胞增生之效果,在低濃度(GI50 = 29.39 ± 2.63 nM)就能抑制細胞增生,但不影響正常細胞之增生情形。並且與已上市之兩種HDAC抑制劑 (Belinostat, PXD101; Vorinostat, SAHA)相比,MPT0G157在HCT116細胞株中抑制HDAC活性之效果最佳,並且有較好的誘發細胞凋亡的效果。MPT0G157同時也會使HSP90乙醯化增加,與其下游蛋白HIF-1alpha分離,失去保護的HIF-1alpha會經由蛋白酶體(proteasome)路徑被降解,減少血管內皮生長因子(vascular endothelial growth factor,VEGF)的mRNA表現,抑制血管新生。為了確認MPT0G157的抑癌效果是經由抑制HDAC活性而產生,我們在過量表現HDAC1及HDAC6後,抑制細胞增生、促進細胞凋亡及抑制HIF-1alpha蛋白表現的情形都有被回復,證實MPT0G157所產生之抗癌效果是經由抑制HDAC活性而產生。並且在動物實驗中MPT0G157可有效抑制腫瘤體積、減少血管新生及抗發炎,證實MPT0G157有良好的抗癌功效。 結論:實驗結果顯示,MPT0G157具有良好的抑癌效果,透過抑制HDAC活性可抑制大腸直腸癌細胞株HCT116之細胞增生,誘發細胞凋亡及抑制血管新生,在活體內實驗中也有明顯抑制腫瘤生成及血管新生的能力,因此MPT0G157有良好的發展潛力可成為固態瘤之治療藥物。 | zh_TW |
dc.description.abstract | Obejective. Histone deacetylases (HDACs) regulate gene expression through chromatin remodeling by reducing histone acetylation. When histone acetylation decrease, tumor suppressor gene will be inhibited; therefore, HDACs are a promising target for cancer treatment. To date, four HDAC inhibitors have been approved, but no HDAC inhibitor has been accepted for solid tumor treatment. The aim of this study is to examine the anti-cancer and anti-angiogenesis effect of MPT0G157, a novel HDAC inhibitor, by in vitro and in vivo models. Methods. Cell proliferation and HDAC activity were determined by SRB assay and HDAC assay kit, respectively. Cell cycle was studied by flow cytometry. Protein and mRNA expression was evaluated by western blot and real time PCR. In angiogenesis, we used cobalt chloride and hypoxia chamber to mimic hypoxia condition, and test HIF-1alpha protein expression. Immunoprecipitation was used to evaluate acetylation of HSP90 and interaction between HIF-1alpha and HSP90. Overexpressing HDAC 1, 6 to ensure the anti-cancer effect of MPT0G157 through inhibition of HDAC activity. In vivo study was determined by xenograft mice model and matrigel plug assay, then analyzed by H E stain, Masson’s trichrome stain, IHC stain, and western blot. Results. MPT0G157 inhibited cell proliferation and was more potent in HCT116 cell line (GI50 = 29.39 ± 2.63 nM) but had no effect on normal cell line HS-5. Comparing with the marketed HDAC inhibitors (Belinostat, PXD101; Vorinostat, SAHA), MPT0G157 exhibited more potent inhibition of HDAC activity and induction of apoptosis. MPT0G157 inhibited angiogenesis through increasing acetylation of HSP90, promoting HIF-1alpha degradation by proteasome system and down-regulating the mRNA expression of VEGF. To further evaluate anti-cancer effect of MPT0G157 through inhibition of HDAC activity, we overexpressed HDAC1, 6 in HCT116 cell. After overexpression HDAC1, 6, the anti-cancer effects were all reversed, which indicated that the MPT0G157 had anti-cancer effect through inhibition of HDAC activity. In animal studies, MPT0G157 significantly inhibited tumor growth, angiogenesis, and down-regulated inflammation factors. Conclusion. Our results demonstrate that MPT0G157 has potent effect in inhibition of cell proliferation, induction of apoptosis, and inhibition of HIF-1alpha expression through inhibition of HDAC activity. MPT0G157 also inhibits tumor growth, angiogenesis and inflammation in animal models. It suggests that MPT0G157 has potential as a new drug in solid tumor therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:47:24Z (GMT). No. of bitstreams: 1 ntu-104-R02423022-1.pdf: 2849876 bytes, checksum: 318a361a01c036ebb9551551e48d2a5a (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 縮寫表 II 中文摘要 III 英文摘要 V 第一章 研究動機與目的 1 第二章 文獻回顧 2 第三章 實驗材料與方法 23 第四章 實驗結果 36 第五章 討論 43 第六章 結論與未來展望 49 參考文獻 68 | |
dc.language.iso | zh-TW | |
dc.title | 新型HDAC抑制劑MPT0G157促進大腸直腸癌細胞株HCT116細胞凋亡與抑制血管新生之研究 | zh_TW |
dc.title | Novel HDAC inhibitor MPT0G157 induced apoptosis and inhibited angiogenesis in colorectal cancer HCT116 cell line | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭哲志(George Hsiao),潘秀玲(Shiow-Lin Pan) | |
dc.subject.keyword | 組蛋白去乙醯?,細胞凋亡,血管新生,缺氧誘導因子-1alpha,熱休克蛋白90, | zh_TW |
dc.subject.keyword | Histone deacetylases,apoptosis,angiogenesis,HIF-1alpha,HSP90, | en |
dc.relation.page | 77 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-07-24 | |
dc.contributor.author-college | 藥學專業學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。